KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

Abstract

AGREE II, Appraisal of Guidelines for Research and Evaluation II; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUC, area under the receiver operating characteristic curve; BMI, body mass index; CAP, controlled attenuation parameter; CKD, chronic kidney disease; CT, computed tomography; CVD, cardiovascular disease; ELF, enhanced liver fibrosis; FIB-4, fibrosis-4 index; FLI, fatty liver index; GLP-1, glucagon-like peptide-1; GRADE, Grading of Recommendations, Assessment, Development and Evaluation; GREACE, GREek Atorvastatin and Coronary-heart-disease Evaluation; HCC, hepatocellular carcinoma; HIS, hepatic steatosis index; KASL, the Korean Association for the Study of the Liver; LDL-C, low density lipoprotein cholesterol; LT, liver transplantation; MAFLD, metabolic (dysfunction)-associated fatty liver disease; METs, metabolic equivalents of task; MRE, magnetic resonance elastography; MRI-PDFF, MRI proton density fat fraction; MRI, magnetic resonance imaging; MRS, MR spectroscopy; NAFL, nonalcoholic fatty liver; NAFLD, nonalcoholic fatty liver disease; NAS, NAFLD activity score; NASH, nonalcoholic steatohepatitis; NFS, NAFLD fibrosis score; NLFS, NAFLD liver fat score; PIVENS, Pioglitazone versus Vitamin E versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis; PNPLA3, the patatin-like phospholipase domain–containing 3; PPAR-γ, peroxisome proliferator activated receptor gamma; SAMM50, sorting and assembly machinery component 50; SWE, shear wave elastography; T2DM, type 2 diabetes mellitus; TM6SF2, transmembrane 6 superfamily, member 2